PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 30, 2015New England Journal of Medicine816 citationsOpen Access

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

View Full Paper
MLMark LebwohlBSBruce StroberAMAlan Menter

Key Points

Key points are not available for this paper at this time.

Abstract

Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis. (Funded by Amgen; AMAGINE-2 and AMAGINE-3 ClinicalTrials.gov numbers, NCT01708603 and NCT01708629.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lebwohl et al. (2015) studied this question.

synapsesocial.com/papers/69d76b0fb1cb92dd1bb8b0f4https://doi.org/10.1056/nejmoa1503824
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis2009 · 1,021 citations
  2. 2Definition of treatment goals for moderate to severe psoriasis: a European consensus2010 · 896 citations
  3. 3Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey2014 · 517 citations
  4. 4IL-17C regulates the innate immune function of epithelial cells in an autocrine manner2011 · 476 citations
  5. 5Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense2001 · 1,515 citations